HLA-A*0201 CMV pp65 Tetramer-NLVPMVATV-APC

MBL Life Sciences

SKU:
MBL-TS-0010-2C
  • HLA-A*0201 CMV pp65 Tetramer-NLVPMVATV-APC
Shipping:
Calculated at Checkout
$1,575.00
Formerly Catalog No.: TB-0010-2
Adding to cart… The item has been added

Related Products

The α3 mutation significantly reduces the binding of MHC tetramer to human CD8. To minimizes the aberrant effect of some CD8 antibodies; clone SFCI21Thy2D3 (also known as “T8”) is recommended.

Product Specifications
Application FC
Reactivity Human
Conjugation APC
Peptide Sequence NLVPMVATV
Class Class I
Sequence Location 495-503
MHC Allele A*02:01


Documents & Links for HLA-A*0201 CMV pp65 Tetramer-NLVPMVATV-APC
Datasheet HLA-A*0201 CMV pp65 Tetramer-NLVPMVATV-APC Datasheet

Documents & Links for HLA-A*0201 CMV pp65 Tetramer-NLVPMVATV-APC
Datasheet HLA-A*0201 CMV pp65 Tetramer-NLVPMVATV-APC Datasheet



Citations for HLA-A*0201 CMV pp65 Tetramer-NLVPMVATV-APC – 2 Found
Sabouri, Amir H; Usuku, Koichiro; Hayashi, Daisuke; Izumo, Shuji; Ohara, Yoshiro; Osame, Mitsuhiro; Saito, Mineki. Impaired function of human T-lymphotropic virus type 1 (HTLV-1)-specific CD8+ T cells in HTLV-1-associated neurologic disease. Blood. 2008;112(6):2411-20.  PubMed
Watanabe, Kazue; Suzuki, Susumu; Kamei, Michi; Toji, Shingo; Kawase, Takakazu; Takahashi, Toshitada; Kuzushima, Kiyotaka; Akatsuka, Yoshiki. CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy. International Journal Of Hematology. 2008;88(3):311-320.  PubMed
!